Dysport Approved to Treat Upper Limb Spasticity in Adults
July 15, 2015 – The U.S. Food and Drug Administration granted approval of Dysport (abobotulinumtoxinA), manufactured by Ipsen Biophamaceutical, for a third indication. The new expanded approval for Dysport is indicated for the treatment of upper limb spasticity in adult patients which is often resulting from a brain injury, spinal cord damage or stroke. These muscle spasms in the upper arms can result in cramping, shaking, stiffness or pain in the elbows, wrists and fingers.
Dysport is an acetycholine-release inhibitor and neuromuscular blocking agent originally approved by the FDA on April 29, 2009 to treat cervical dystonia (twisting or cramping in neck muscles) and temporary improvement of the appearance of moderate to severe glabellar (frown) lines for adult patients younger than 65 years of age.
Dysport is administered via injection into affected muscles. It is not interchangeable with any other botulinum product and must carry a boxed warning that it may affect places far from the point of injection. Complications such as severe breathing or swallowing problems may follow the use of Dysport.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.